Publication: Clinical characteristics, microbiology and outcomes of a cohort of patients treated with ceftolozane/tazobactam in acute care inpatient facilities, Houston, Texas, USA
Gestores bibliográficos
Compartir
item.contributor.advisor
ORCID:
Journal Title
Journal ISSN
Volume Title
Publisher
item.page.isbn
item.page.issn
item.page.issne
item.page.doiurl
item.page.extent
item.page.accessRights
Acceso Abierto
item.page.other
item.page.references
Abstract
Background: Ceftolozane/tazobactam is a β-lactam/β-lactamase inhibitor combination with activity against a variety of Gram-negative bacteria, including MDR Pseudomonas aeruginosa. This agent is approv...
Description
item.page.coverage.spatial
item.page.sponsorship
Citation
Tran TT, Cabrera NL, Gonzales-Luna AJ, Carlson TJ, Alnezary F, Miller WR, Sakurai A, Dinh AQ, Rydell K, Rios R, Diaz L, Hanson BM, Munita JM, Pedroza C, Shelburne SA, Aitken SL, Garey KW, Dillon R, Puzniak L, Arias CA. Clinical characteristics, microbiology and outcomes of a cohort of patients treated with ceftolozane/tazobactam in acute care inpatient facilities, Houston, Texas, USA. JAC Antimicrob Resist. 2023 Jan 2;5(1):dlac131. doi: 10.1093/jacamr/dlac131
item.page.dc.rights
item.page.dc.rights.url
Estadísticas de uso
1 0,8 0,5 0,3 0
Septiembre 2025Octubre 2025Noviembre 2025Diciembre 2025Enero 2026Febrero 2026Marzo 2026